Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

B. Y. Karlan; A. M. Oza; V. L. Hansen; G. E. Richardson; D. M. Provencher; P. Ghatage; M. Tassoudji; D. E. Stepan; D. M. Weinreich; I. B. Vergote

doi:10.1200/jco.2010.28.15_suppl.5000

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5000 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5000-5000 ◽

Cited By ~ 20

Author(s):

B. Y. Karlan ◽

A. M. Oza ◽

V. L. Hansen ◽

G. E. Richardson ◽

D. M. Provencher ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Double Blind ◽

Double Blind Placebo ◽

Amg 386

Download Full-text

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.003 ◽

2012 ◽

Vol 2012 ◽

pp. 118-119

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Recurrent Ovarian Cancer ◽

Weekly Paclitaxel ◽

Double Blind ◽

Double Blind Placebo ◽

Amg 386

Download Full-text

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

ESMO Open ◽

10.1016/j.esmoop.2021.100311 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100311

Author(s):

J.A. Ledermann ◽

B. Zurawski ◽

F. Raspagliesi ◽

U. De Giorgi ◽

J. Arranz Arija ◽

...

Keyword(s):

Maintenance Therapy ◽

Ovarian Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Epithelial Ovarian Carcinoma ◽

Mucin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii

Download Full-text

A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps255 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS255-TPS255 ◽

Cited By ~ 3

Author(s):

L. Elit ◽

J. A. Konner ◽

D. K. Armstrong ◽

M. Buck ◽

A. Dean ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Platinum Resistant

Download Full-text

A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study

The Oncologist ◽

10.1634/theoncologist.2020-0679 ◽

2020 ◽

Vol 25 (11) ◽

Author(s):

Richard F. Riedel ◽

Karla V. Ballman ◽

Yao Lu ◽

Steven Attia ◽

Elizabeth T. Loggers ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Refractory

Download Full-text

Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)

Annals of Oncology ◽

10.1093/annonc/mdw370.95 ◽

2016 ◽

Vol 27 ◽

pp. vi180

Author(s):

S. Yuki ◽

Y. Komatsu ◽

H. Satake ◽

Y. Miyamoto ◽

H. Tanioka ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　– A Randomized, Double-Blind, Placebo-Controlled Phase II Study –

Circulation Journal ◽

10.1253/circj.cj-15-1112 ◽

2016 ◽

Vol 80 (3) ◽

pp. 668-676 ◽

Cited By ~ 18

Author(s):

Hiroyuki Tsutsui ◽

Shinichi Momomura ◽

Akira Yamashina ◽

Hisao Ogawa ◽

Hiroaki Shimokawa ◽

...

Keyword(s):

Heart Failure ◽

Heart Rate ◽

Chronic Heart Failure ◽

Phase Ii ◽

Rate Control ◽

Phase Ii Study ◽

Japanese Patients ◽

Heart Rate Control ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of Additional 200-mg Dose of Celecoxib in Adult Patients With Postoperative Pain Following Extraction of Impacted Third Mandibular Molar: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Japan

Clinical Therapeutics ◽

10.1016/j.clinthera.2012.01.004 ◽

2012 ◽

Vol 34 (2) ◽

pp. 314-328 ◽

Cited By ~ 10

Author(s):

Ken‘ichi Saito ◽

Akihiro Kaneko ◽

Katsuyuki Machii ◽

Hiroyoshi Ohta ◽

Masayuki Ohkura ◽

...

Keyword(s):

Postoperative Pain ◽

Phase Ii ◽

Phase Ii Study ◽

Adult Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Mandibular Molar

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-17-1558 ◽

2017 ◽

Vol 24 (2) ◽

pp. 316-325 ◽

Cited By ~ 7

Author(s):

Axel Grothey ◽

Jonathan R. Strosberg ◽

Lindsay A. Renfro ◽

Herbert I. Hurwitz ◽

John L. Marshall ◽

...

Keyword(s):

Colorectal Cancer ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Best Supportive Care ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

Molecular Therapy ◽

10.1016/j.ymthe.2019.10.017 ◽

2019 ◽

Vol 27 (12) ◽

pp. 2158-2165 ◽

Cited By ~ 4

Author(s):

Yongquan Gu ◽

Shijun Cui ◽

Qi Wang ◽

Changjian Liu ◽

Bi Jin ◽

...

Keyword(s):

Growth Factor ◽

Hepatocyte Growth Factor ◽

Phase Ii ◽

Critical Limb Ischemia ◽

Phase Ii Study ◽

Limb Ischemia ◽

Double Blind ◽

Double Blind Placebo ◽

Hepatocyte Growth

Download Full-text

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Advances in Therapy ◽

10.1007/s12325-020-01538-0 ◽

2020 ◽

Author(s):

Lowell L. Hart ◽

Renata Ferrarotto ◽

Zoran G. Andric ◽

J. Thaddeus Beck ◽

Janakiraman Subramanian ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.

A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study

Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)

Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure – A Randomized, Double-Blind, Placebo-Controlled Phase II Study –

Efficacy and Safety of Additional 200-mg Dose of Celecoxib in Adult Patients With Postoperative Pain Following Extraction of Impacted Third Mandibular Molar: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Japan

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　– A Randomized, Double-Blind, Placebo-Controlled Phase II Study –